+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
VINRKLB VINRKLB

Rekvina Laboratories Share Price

₹59.03 +2.81 (5%)
Near 52W High of ₹59.40

13 Oct, 2026 4:01 PM (IST)

Rekvina Laboratories live price: ₹59.03. It opened at ₹59 vs previous close ₹56; intraday high/low: ₹59/₹59. The 50 & 200 DMA stand at ₹48.00/₹34.20.

Rekvina Laboratories Performance

  • Today's Low
  • ₹59
  • Today's High
  • ₹59
  • 52 Week Low
  • ₹7
  • 52 Week High
  • ₹59
  • Open Price₹59
  • Previous Close₹56
  • Volume1,954
  • 50 DMA₹48.00
  • 100 DMA₹42.40
  • 200 DMA₹34.20

Rekvina Laboratories Chart

Investment Returns

  • Over 1 Month -0.62%
  • Over 3 Month + 68.66%
  • Over 6 Month + 48.06%
  • Over 1 Year + 1211.78%

Smart Investing Starts Here Start SIP with Rekvina Laboratories for Steady Growth!

Invest Now

Rekvina Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -104.7
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 36
  • P/B Ratio
  • -26.4
  • Average True Range
  • 1.3
  • EPS
  • -0.6
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.8
  • RSI
  • 73.26
  • MFI
  • 32.9

Latest Stock News Updates

Rekvina Laboratories Ltd - 526075 - Announcement under Regulation 30 (LODR)-Change in Management

Appointment of Mr. Subrata Samanta as a Chief Financial officer of the company with effect from 07.10.2026.

Rekvina Laboratories Ltd - 526075 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM Voting Results along-with Scrutinizer Report on E-Voting

Rekvina Laboratories Ltd - 526075 - Shareholder Meeting / Postal Ballot-Outcome of AGM

Summary of Proceeding of Annual General Meeting

Rekvina Laboratories Financials

Rekvina Laboratories Technicals

EMA & SMA

Current Price
₹59.03
+ 2.81 (5%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹52.40
  • 50 Day
  • ₹48.00
  • 100 Day
  • ₹42.40
  • 200 Day
  • ₹34.20

Resistance and Support

59.01 Pivot Speed
  • R3 59.00
  • R2 59.00
  • R1 59.00
  • S1 59.00
  • S2 59.00
  • S3 59.00

Rekvina Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-13 Quarterly Results
2026-05-21 Audited Results
2026-03-16 Preferential Issue of shares Inter-alia, to consider 1.Proposal for issuance equity shares/any other securities of the Company, by way of Preferential issue, in accordance with provisions of Securities & Exchange Board of India.
2026-02-06 Quarterly Results
2025-11-14 Quarterly Results
Date Purpose Remarks
2014-05-02 Split

Rekvina Laboratories Shareholding Pattern

58.7%
41.3%
0%

About Rekvina Laboratories

Rekvina Labs engaged in providing comprehensive diagnostic and testing services, including clinical pathology, biochemistry, microbiology, molecular diagnostics, and advanced imaging. The company operates with a commitment to accuracy, reliability, and innovation in medical testing, supported by state-of-the-art laboratory technology and a team of highly skilled professionals. By upholding the highest standards of quality and precision and plays a vital role in disease detection, prevention, and treatment support, serving hospitals, clinics, and individual patients with trusted diagnostic solutions. View More
  • NSE Symbol
  • VINRKLB
  • BSE Symbol
  • 526075
  • ISIN
  • INE092O01028

Similar Stocks to Rekvina Laboratories

Rekvina Laboratories FAQs

Rekvina Laboratories share price is ₹59 As on 14 October, 2026 | 03:29

The Market Cap of Rekvina Laboratories is ₹35.6 Cr As on 14 October, 2026 | 03:29

The P/E ratio of Rekvina Laboratories is -104.7 As on 14 October, 2026 | 03:29

The PB ratio of Rekvina Laboratories is -26.4 As on 14 October, 2026 | 03:29

The 52 week High & Low of Rekvina Laboratories is ₹59.4/₹6.8 respectively As on 14 October, 2026 | 03:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23